Answers are grounded in this paper and cite their sources.
BACKGROUND: Chronic spontaneous urticaria (CSU) substantially reduces patients' quality of life (QoL); therefore, it is crucial to include QoL-related patient-reported outcome measures when assessing treatment efficacy. OBJECTIVE: To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU. Patients were randomized 2:1 to oral remibrutinib 25 mg twice daily or placebo (24 weeks), followed by an open-label treatment period (28 weeks), and a treatment-free follow-up period (4 weeks); those on placebo transitioned to remibrutinib at week 24. Patients completed patient-reported outcome measures, including the Weekly Urticaria Control Test, Weekly Urticaria Activity Score, Weekly Sleep/Activity Interference Score, Dermatology Life Quality Index, EQ-5D-5L (EuroQol-5 dimensions-5 levels), and Work, Productivity, and Activity Impairment. RESULTS: The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively. Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]). Improvements with remibrutinib were also observed in Urticaria Control Test, Activity Interference Score, Dermatology Life Quality Index, EQ-5D-5L, and Work, Productivity, and Activity Impairment at the earliest time points collected. Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib. CONCLUSION: Remibrutinib exhibited fast improvements in disease control, sleep, and QoL in REMIX-1 and REMIX-2, supporting remibrutinib as a valuable therapeutic option for CSU. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT05030311 (REMIX-1) and NCT05032157 (REMIX-2).
No takes yet. Share an insight, caveat, or question.
Mosnaim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: